Table 4.
Khorana’s risk assessment model (RAM)
| Patient characteristics | Risk score points | |
|---|---|---|
| Site of cancer | ||
| Very high risk (stomach, pancreas) | 2 | |
| High risk (lung, lymphoma, gynecologic, genitourinary excluding prostate) | 1 | |
| Pre-chemotherapy platelet count ≥350,000/mm3 | 1 | |
| Hemoglobin level less than <10 g/dl or use of red cell growth factors | 1 | |
| Pre-chemotherapy leukocyte count >11,000/mm3 | 1 | |
| BMI 35 ≥ 35 kg/m2 | 1 | |
| Risk score (points) | Risk category | Rates of sVTE according to scores (%) |
|---|---|---|
| 0 | Low | 0.3–0.8 |
| 1–2 | Intermediate | 1.8–2.0 |
| ≥3 | High | 6.7–7.1 |
BMI body mass index, sVTE symptomatic VTE